Human organ-on-a-chip technology as a catalyst for drug discovery
Advanced Drug Delivery Reviews · 2026-09 · 236 · 115920
DOI: 10.1016/j.addr.2026.115920 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-09. Verfasst von Ryan Posey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Drug Discovery, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 282 Literaturangaben. Gefördert von: U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Defense Advanced Research Projects Agency Defense Sciences Office.
Abstract (Originalsprache)
The pharmaceutical industry currently faces a critical attrition crisis, with approximately 90% of drug candidates failing during clinical translation. A major contributor to this high failure rate is the inability of preclinical models, namely conventional cell cultures and animal studies, to accurately predict human responses. In recent years, human Organ-on-a-Chip (Organ Chip) microfluidic culture technology has emerged as an alternative and potentially transformative approach to overcome these limitations. Unlike static cell cultures or organoids, Organ Chips recapitulate organ-level pathophysiology by incorporating tissue-tissue interfaces, dynamic fluid flow, mechanical cues, and immune cells, enabling a higher level of physiological mimicry as well as the testing of therapeutic responses using clinically relevant drug pharmacokinetic profiles. In this article, we focus on how human Organ Chip technology has begun to be used to facilitate drug development, its advantages and disadvantages relative to traditional preclinical models, and its recent integration with artificial intelligence (AI) and high throughput screens, which have the potential to accelerate discovery while ameliorating translation rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02215, USA.
- Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA 02215, USA; Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA 02…
Förderung
- U.S. Food and Drug Administration
- U.S. Department of Health and Human Services
- Defense Advanced Research Projects Agency Defense Sciences Office
- Biomedical Advanced Research and Development Authority
- Defense Advanced Research Projects Agency
- Hansjörg Wyss Institute for Biologically Inspired Engineering, Harvard University
Zitieren
APA
Posey, R., Özkan, A., & Ingber, D. E. (2026). Human organ-on-a-chip technology as a catalyst for drug discovery. Advanced Drug Delivery Reviews, 236, 115920. https://doi.org/10.1016/j.addr.2026.115920
Vancouver
Posey R, Özkan A, Ingber DE. Human organ-on-a-chip technology as a catalyst for drug discovery. Advanced Drug Delivery Reviews. 2026;236:115920. doi:10.1016/j.addr.2026.115920
BibTeX
@article{Posey2026,
author = {Posey, Ryan and Özkan, Alican and Ingber, Donald E},
title = {Human organ-on-a-chip technology as a catalyst for drug discovery},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {236},
pages = {115920},
doi = {10.1016/j.addr.2026.115920}
}
EUVIMED